Alzheimer Disease study: PET/MR Imaging vs 64Cu-FBP8
Official title Assess Fibrin in Brains With AD/ADRD
ClinicalTrials.gov ID: NCT05336695
What this study is testing
What is 64Cu-FBP8?
An investigational PET imaging dye being studied to assess brain fibrin levels in Alzheimer disease research. It is designed to bind to fibrin in the brain so that the bound radio‑copper can be visualized with PET scanning.
Also referred to as Positron Emission Tomography dye.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to measure how much fibrin is in the brain and see if it differs by region in people who are cognitively normal or have Alzheimer’s disease.
- Who it's for
- Adults who are either cognitively normal or have been clinically diagnosed with Alzheimer’s disease or related dementia.
- What's involved
- Participants will undergo a PET scan that uses a special tracer (64Cu‑FBP8) to detect fibrin in the brain. No medication or other treatment is given.
- Time commitment
- The study involves a single PET scan visit, lasting about 1–2 hours.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 to 90. Healthy volunteers may be eligible.
You may be able to join if
- Age between 55 and 90 years
- Ability to provide informed consent
- Specific to healthy volunteers: no history of ADRD
- Specific to ADRD people: clinical diagnosis of AD - either amnestic or atypical, clinical severity ranging from MCI to moderate dementia (CDR...
- Specific to BAnD people: referred through the Brain Aging and Dementia (BAnD) research registry
You likely can't join if
- MR contraindications such as: electrical implants such as cardiac pacemakers or perfusion pumps
- Preexisting medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for...
- people whose estimated glomerular filtration rate (eGFR) \< 60 mL/min will be excluded from receiving the gadolinium-based contrast agent
- Research-related radiation exposure exceeding current Massachusetts General Hospital (MGH) Radiology Department guidelines (i.e.
- 3\. In line with published MGH IRB guidelines for pregnancy must be ruled out by urine ß-HCG if answers to screening questions suggest that pregnancy...
The study team makes the final eligibility decision.
Where it is enrolling
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years to 90 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Boston, Massachusetts, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.